CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 20 enrolled
Drug / intervention
Arformoterol tartrate +3 moredrug
Likely dose
Arformoterol tartrate 15 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00754546
NCT00754546Phase 4Completed
CompareCT.gov

Effects of Arformoterol on Exercise Endurance Time and Breathlessness in COPD: Cycle Ergometer vs. Treadmill

Dartmouth-Hitchcock Medical Center·interventional·Posted Sep 18, 2008·Updated May 29, 2013

In Brief

A Phase 4 clinical trial evaluating Arformoterol tartrate, Placebo: Normal Saline, and 2 other interventions for Chronic Obstructive Pulmonary Disease. Completed, enrolled 20 participants across 1 site.

Detailed Summary

Previous studies suggest that treadmill exercise may be a more relevant exercise stimulus than the cycle ergometer to demonstrate benefits with bronchodilator therapy in patients with COPD. The hypothesis of the study is that patients with COPD will exhibit greater improvements in exercise endurance and breathlessness with arformoterol compared with normal saline during treadmill walking than with cycle exercise.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Obstructive Pulmonary Disease
CountriesUnited States
CollaboratorsSumitomo Pharma America, Inc.

Timeline

Phase 4CompletedFinished
2009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 18, 2008
Enrollment StartAug 1, 2008
Primary CompletionMay 1, 2009
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 17.8 years ago

Interventions

Arformoterol tartratedrug

15 mcg in two ml solution administered via nebulizer

Placebo: Normal Salinedrug

Normal saline was nebulized.

Treadmill Exerciseother

Cycle Exerciseother